Search clinical trials for: Computer Assisted Learning (CAL) Module

Total 1746 results

National Cancer Institute (NCI)

Recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable Synovial Sarcoma | Metastatic Myxofibrosarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma | Metastatic Dedifferentiated... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Breast Adenocarcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent WHO Grade 4 Glioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed Subtype

United States
University of Washington
Genentech, Inc.

Completed

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
Fred Hutchinson Cancer Center
Swedish Orphan Biovitrum

Completed

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

B-Cell Non-Hodgkin Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Sickle Cell Disease

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

Stage 0a Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Recurrent Non-Muscle Invasive Bladder Carcinoma

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Leukemia

United States
University of Michigan Rogel Cancer Center
Summit Therapeutics

Recruiting

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer (SENIOR-HN)

Advanced Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma | Stage II Head and Neck Cutaneous Squamous Cell Carcinoma | Stage III Head and Neck Cutaneous Squamous Cell Carcinoma | Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

Recurrent Glioblastoma | Progressive Glioblastoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
Thomas Jefferson University

Terminated

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Mayo Clinic

Recruiting

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Renal Pelvis Urothelial Carcinoma | Muscle Invasive Ureter Urothelial... and other conditions

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND)

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder

United States
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Terminated

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
University of Washington
Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Adenocarcinoma | Metastatic Castration-Sensitive Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Adult Ovarian Granulosa Cell Tumor

United States
Roswell Park Cancer Institute

Active, not recruiting

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Colo-rectal Cancer

United States
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Roswell Park Cancer Institute

Recruiting

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Refractory Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Missouri Department of Health and Senior Services

Recruiting

Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control (NHOralHealth)

Pneumonia | Diabetes | Periodontitis | Gingivitis | Periodontal Disease | Periodontal Infections | Oral Infections | Periapical Infections

United States
Roswell Park Cancer Institute

Terminated

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Mayo Clinic

Recruiting

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
Fred Hutchinson Cancer Center
Amazon, Inc.

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 and other conditions

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Richter Syndrome | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
University of Washington
Breast Cancer Research Foundation

Recruiting

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada

Search clinical trials for: Computer Assisted Learning (CAL) Module

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations